Akèy › Kansè vejik › Texas › Austin
Etid klinik pou Kansè vejik nan Austin, TX
12 etid pou Kansè vejik ap chèche patisipan nan sit nan ak bò kote Austin (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Ap rekriteFaz 3
- Texas Oncology, Austin
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Ap rekriteFaz 2
- Texas Oncology-Austin Central ( Site 0107), Austin
- Urology Austin, PLLC ( Site 0109), Austin
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Ap rekriteFaz 1/2
- Texas Oncology - Central/South Texas, Austin
- Texas Oncology - Central/South Texas, Austin
- Texas Oncology - Central/South Texas, Austin
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Ap rekriteFaz 3
- USO-Texas Oncology-Central/South Texas, Austin
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Ap rekriteFaz 1/2
- Texas Oncology (Balcones) - SCRI, Austin
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Ap rekriteFaz 1/2
- Urology Austin, PLLC ( Site 0008), Austin
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Ap rekriteFaz 2
- Urology Austin, PLLC (Urology America), Austin
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Ap rekriteFaz 2
- Urology Austin, LLC, Austin
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Ap rekriteFaz 1/2
- Urology Austin, Austin
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Ap rekriteFaz 2/3
- Local Institution - 0187, Austin
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Ap rekrite
- Austin Urology Institute, Austin
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Elligo Health Research, Inc., Austin
Etid Kansè vejik nan lòt vil
- New York City, NY34 etid
- Nashville, TN31 etid
- Houston, TX31 etid
- Dallas, TX27 etid
- Washington, DC26 etid
- Boston, MA26 etid
- Los Angeles, CA24 etid
- Baltimore, MD24 etid
- St. Louis, MO22 etid
- Edison, NJ22 etid
- Philadelphia, PA21 etid
- Chicago, IL21 etid
Lòt etid nan Austin
- Kansè Poumon ki pa ti selil30 etid
- Kansè (tout kalite)21 etid
- Obèsite20 etid
- Kansè kolorektal19 etid
- Kansè Metastatik19 etid
- Ensifizyans kadyak18 etid
- Sipwa18 etid
- Kansè nan tete18 etid
- Kansè ovè17 etid
- Kansè Endomèt16 etid
- Kansè pwostat15 etid
- Depresyon14 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.